Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd and keeping the price target at CHF6.00.

Ram Selvaraju has given his Buy rating due to a combination of factors reflecting both product differentiation and pipeline depth. He highlights Idorsia’s insomnia drug daridorexant (QUVIVIQ) as having a superior pharmacokinetic profile within the DORA class, allowing strong efficacy on sleep quality without residual next‑day sedation, and notes that potential regulatory descheduling of the class could materially ease prescribing and expand use. He also underscores the strategic value of aprocitentan (TRYVIO/JERAYGO) in resistant hypertension, particularly its compatibility with other antihypertensives and its relevance in patients with chronic kidney disease, alongside the favorable read‑through for lucerastat in Fabry disease from recent M&A valuations in the rare disease space.

Selvaraju further points out that management’s revenue outlook through 2027 appears deliberately cautious because it excludes upside from possible DORA descheduling, a U.S. commercial partnership for aprocitentan, and broader pipeline contributions. In his view, current forecasts can be achieved mainly through steady U.S. growth of daridorexant—supported by telemedicine and digital promotion—and continued prescription momentum in Europe. He also emphasizes recent clinical data showing meaningful improvements in multiple sleep and daytime functioning endpoints for daridorexant in midlife women with insomnia, as well as its inclusion in the large CELESTE trial for menopause‑related insomnia, as evidence supporting further market expansion. Combined with a broad, advancing pipeline centered on orexin modulation and chemokine receptor inhibition, and what he regards as attractive valuation, these dynamics underpin his decision to reiterate a Buy rating and a CHF 6 twelve‑month price target.